SMPD4BP: A Promising Drug Target and Potential Biomarker for Sphingomyelin Phosphodiesterase 4B-Positive Chronic Pain

Target Name: SMPD4BP

NCBI ID: G150776

SMPD4BP

Other Name(s): sphingomyelin phosphodiesterase 4B, pseudogene | Sphingomyelin phosphodiesterase 4B, pseudogene

SMPD4BP: A Promising Drug Target and Potential Biomarker for Sphingomyelin Phosphodiesterase 4B-Positive Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent pain can lead to significant morbidity and affect quality of life. The most common causes of chronic pain are musculoskeletal, neuropathic, and inflammatory pain. Although various medications have been Developed to manage chronic pain, the outcomes are often unsatisfactory. Therefore, there is an urgent need to identify new targets for pain modulation and develop new diagnostic biomarkers.

Sphingomyelin phosphodiesterase 4B (SMPD4BP) is a gene that encodes a protein involved in sphingomyelin biosynthesis and degradation. The pseudogene, SMPD4BP, has been identified in various organisms, including humans. It has been demonstrated that SMPD4BP is involved in the regulation of sphingomyelin homeostasis, which is crucial for maintaining the structural and functional integrity of cell membranes. The imbalance in sphingomyelin homeostasis has been implicated in various diseases, including chronic pain.

SMPD4BP is a potential drug target for chronic pain modulation because it has been shown to regulate pain perception and aspartate levels. In animal experiments, knockout of the SMPD4BP gene resulted in reduced ability of mice to perceive pain and increased levels of aspartate, a neurotransmitter. In addition, knockout of SMPD4BP also increases the content of aspartate in neural tissue, thereby increasing the sensitivity of neural tissue to nerve stimulation and exacerbating pain.

SMPD4BP is also closely related to neuronal connections and synaptic function in neural tissue. Studies have shown that SMPD4BP gene knockout will lead to reduced neuronal connections and decreased synaptic function, thereby affecting the normal function of neural tissue. These results indicate that SMPD4BP plays an important role in neural tissue and may be a potential therapeutic target for neural tissue diseases.

In addition, SMPD4BP is closely related to tumor occurrence and development. Studies have shown that SMPD4BP gene knockout can increase the risk of tumorigenesis and is related to the invasive ability of tumor occurrence and development. These results suggest that SMPD4BP may be a potential tumor therapeutic target.

SMPD4BP, as a gene knockout mouse model, can be used to study the role of SMPD4BP in chronic pain. By inhibiting SMPD4BP gene expression, the content of aspartic acid in neural tissue can be reduced, thereby reducing the excitability of neural tissue and improving pain. In addition, it can also promote the degradation of aspartic acid in nervous tissue by restoring SMPD4BP gene expression, thereby inhibiting the excitability of nervous tissue and relieving pain.

SMPD4BP, as a protein, can also be used as a biomarker of pain. By detecting the expression level of the SMPD4BP gene, the patient's pain level can be evaluated and can be used to evaluate the therapeutic effect of drugs on chronic pain. In addition, SMPD4BP gene knockout can also be used as a biomarker for neurological tissue diseases to evaluate the disease.

Protein Name: Sphingomyelin Phosphodiesterase 4B, Pseudogene

The "SMPD4BP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMPD4BP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets